ProCE Banner Activity

Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients with Multiple Myeloma

Slideset

Downloadable slides covering racial disparities in presentation, treatment, and side effects among patients with multiple myeloma and strategies to improve outcomes.

Released: May 31, 2023

Share

Faculty

Frances (Blevins) Arters

Frances (Blevins) Arters, PA-C

Dept of Medicine
Hematology and Medical Oncology
Boston Medical Center
Assistant Professor 
Boston University Chobanian and Avedisian School of Medicine
Boston, MA

Ajay K. Nooka

Ajay K. Nooka, MD, MPH, FACP

Professor
Department of Hematology and Medical Oncology
Associate Director of Clinical Research, Winship Cancer Institute
Medical Director, Winship Data and Technology Applications Share Resource
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Bhavesh Shah

Bhavesh Shah, R.Ph, BCOP

Chief Pharmacy Officer
Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, Massachusetts

Raphael Szalat

Raphael Szalat, MD, PhD

Program Course Director 
Director, Multiple Myeloma Program
Section of Hematology & Medical Oncology
Department of Medicine
Boston Medical Center
Assistant Professor of Medicine
Boston University Chobanian & Avedisian and School of Medicine 
Boston, MA

Provided by

Provided by The Boston University School of Medicine Continuing Medical Education Office (BUSM CME), in collaboration with Boston Medical Center (BMC) and Clinical Care Options (CCO)

ProCE Banner
ProCE Banner

Supporters

This activity is supported by independent medical education grants from Bristol Myers Squibb, Karyopharm Therapeutics, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc. This activity is also supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Bristol Myers Squibb

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Karyopharm Therapeutics

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc